The enclosed interactive map contains information about the hospitals performing pharmacokinetic and pharmacogenetic activities.
Click on the menu button on the top left hand side corner of the map and use the different filters to access the information on each hospital.
You will find information on the centers that carry out analytical determinations of drug concentrations in their pharmacy departments, the drugs that are most commonly monitored, what software is most commonly used, and what departments have their own pharmacogenetics unit.
The PKGen workgroup would like to thank all the SEFH members who participated in the survey as the information they contributed has made this resource possible.
1. To establish a basic framework clinical pharmacokinetics and pharmacogenetics/pharmacogenomics (PK/PG) framework for each one of the different medicines that have been shown to be subject to such activities and/or for the different patient populations that have demonstrated differential ADME characteristics or genetic polymorphisms.
2. To design and promote multicenter population-based pharmacokinetics/ pharmacogenetics studies that respond to previously-agreed working hypotheses. Research studies and publications will be conducted with grants from official organizations.
3. To define and standardize the aspects of pharmacokinetics and pharmacogenetics to be taught to pharmacy residents so as to ensure a minimum standard of competence. Promote the official recognition by SEFH of hospital departments engaging in PK/PG activities.
4. To collaborate with other groups or professional associations who share our same goals.
5. Promote and increase the visibility of hospital pharmacies engaged in PK/PG activities by using the new communication technologies and the pKGen workgroup’s website and twitter account.
The Spanish pharmacokinetics (PK) and pharmacogenetics (PG) workgroup, PKgen, was established in May 2008. Its primary mission is to promote the development of PK and PG units in the pharmacy departments of Spanish hospitals.
Pharmacokinetics
Clinical PK may be defined as the use of pharmacokinetic (PK) and pharmacodynamic (PD) principles to ensure the drug therapies administered to patients are safe and effective. The ultimate purpose is to adjust each patient’s dosage based on the observed plasma concentration of the drug in question and the patient’s physiopathological characteristics. PK monitoring comprises two stages: the determination of the drug’s plasma concentration on the one hand, and the preparation of a PK report with an interpretation of the results. The reliability of this strategy depends on the quality of the information obtained and on an appropriate interpretation of the PK/PD criteria.
Pharmacogenetics
PG studies the influence of variations in the DNA sequence on the safety and efficacy of a given pharmacological treatment. The primary goal is to identify and characterize genetic polymorphisms and their correlation with clinical results. It is essential to quantify how much of the variability in the exposure to a drug can be attributable to PG and regard PG as a complement to PK and never as the sole criterion to guide dose adjustments.
Modern society demands high-quality healthcare. To meet such demands, health professionals, among them pharmacists, must apply their knowledge with maximum scientific rigor and with a great sense of responsibility. The pKgen workgroup would therefore like to assist pharmacists in being up to the task and using rigorous criteria grounded in the available scientific evidence.
LAST NEWS
68º Congreso Nacional SEFH
¡No te pierdas el curso precongreso y los talleres del grupo PKGen en el próximo congreso SEFH!
Tendrá lugar en Bilbao del 5-7 de Octubre de 2023.
Puedes encontrar todo la información y el programa en la página del congreso.
